TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15585685

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at a daily dose of 33 microg/kg (0.1 U/kg)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment for >2 years before puberty
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment for <2 years before puberty
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 77
Study: 12522981

Group type: EXPERIMENTAL
Intervention: Intention-to-treat analysis
Number of subjects: 0
Study: 9629064

Group type: EXPERIMENTAL
Intervention: Semi-rigid lumbosacral orthosis (SRLSO)
Number of subjects: 15

Group type: COMPARATOR
Intervention: No belt
Number of subjects: 15
Study: 7887378

Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography with pacing (TEEP)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Single-photon emission computed tomography (SPECT)
Number of subjects: 55
Study: 2237720

Group type: EXPERIMENTAL
Intervention: EEA circular stapler
Number of subjects: 250

Group type: COMPARATOR
Intervention: Single layer sutured anastomoses
Number of subjects: 250
Study: 842813

Group type: EXPERIMENTAL
Intervention: Naloxone 0.1-0.2 mg i.v.
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Naloxone 0.2 mg i.m. (if required)
Number of subjects: 74
Study: 29698924

Group type: EXPERIMENTAL
Intervention: Metabolomics and transcriptomics investigation in a controlled human malaria infection trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metabolomics data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Top pathways during infection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Semi-immune group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Integration of transcriptomics and metabolomics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Additional experiment
Number of subjects: 0
Study: 26802979

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 24604835

Group type: EXPERIMENTAL
Intervention: Outpatient intravenous cefepime 50 mg/kg (12 hourly)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Inpatient intravenous cefepime 50 mg/kg (12 hourly)
Number of subjects: 81
Study: 22411278

Group type: EXPERIMENTAL
Intervention: Modified Melodic Intonation Therapy (MMIT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 30
Study: 21055277

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 68

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 68
Study: 18203246

Group type: EXPERIMENTAL
Intervention: Shared Decision Making (SDM)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Independent Decision Making
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Doctor Decision Making
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Education and Age Influence
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: PCS Knowledge Influence
Number of subjects: 286
Study: 15632666

Group type: EXPERIMENTAL
Intervention: Low progestin oral contraceptives
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: High progestin oral contraceptives
Number of subjects: 14

Group type: COMPARATOR
Intervention: Active pill phase
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo pill phase
Number of subjects: 14
Study: 14581245

Group type: EXPERIMENTAL
Intervention: INH + OHA group (n = 32)
Number of subjects: 68

Group type: COMPARATOR
Intervention: OHA group (n = 36)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 68
Study: 10888689

Group type: EXPERIMENTAL
Intervention: Computer-based telephone system (autodialer)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manual postcard system (mail)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 8757408

Group type: EXPERIMENTAL
Intervention: CO/SL (Carbon Monoxide at Sea Level)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: CA/HA (Clean Air at High Altitude)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: CO/HA (Carbon Monoxide at High Altitude)
Number of subjects: 17

Group type: COMPARATOR
Intervention: CA/SL (Clean Air at Sea Level)
Number of subjects: 17
Study: 1329479

Group type: EXPERIMENTAL
Intervention: Lisinopril 5‐20 mg once daily
Number of subjects: 217

Group type: COMPARATOR
Intervention: Digoxin 0.125‐0.375 mg once daily
Number of subjects: 217
Study: 3933397

Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet (28% carbohydrate calories, 55% fat calories)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate carbohydrate diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High carbohydrate diet
Number of subjects: 0
Study: 28854500

Group type: EXPERIMENTAL
Intervention: High intensity laser therapy (HILT) combined with spinal decompression system (SDS)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Spinal decompression system (SDS) alone
Number of subjects: 63
Study: 26862829

Group type: EXPERIMENTAL
Intervention: 90 mg RBP-7000
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 120 mg RBP-7000
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24829213

Group type: EXPERIMENTAL
Intervention: Measles vaccination (MV) in the presence of maternal antibody
Number of subjects: 0

Group type: COMPARATOR
Intervention: Measles vaccination (MV) without maternal antibody
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined analysis of measles vaccination (MV) with maternal antibody
Number of subjects: 0
Study: 23184299

Group type: EXPERIMENTAL
Intervention: Mobile geriatric consultant service (GECO)
Number of subjects: 100

Group type: COMPARATOR
Intervention: General practitioners' medical attendance (control)
Number of subjects: 100
Study: 20141454

Group type: EXPERIMENTAL
Intervention: Single-session Motivational Interviewing (MI)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 35
Study: 18043421

Group type: EXPERIMENTAL
Intervention: Visual impairment and physical disability
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Physical, visual, and psychological factors
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Visual disability
Number of subjects: 391
Study: 16263359

Group type: EXPERIMENTAL
Intervention: Intracoronary radiation therapy (IRT) using tungsten (188W) at doses of 18, 22, or 25 Gy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intracoronary radiation therapy (IRT) using tungsten (188W)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison with the original WRIST radiation cohort using 192Iridium source
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison with the WRIST placebo cohort
Number of subjects: 30
Study: 12242074

Group type: EXPERIMENTAL
Intervention: abciximab for 24 h, 48 h
Number of subjects: 7800
Study: 10486790

Group type: EXPERIMENTAL
Intervention: Sternal skin conductance monitor
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Subjective reporting of hot flashes
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Skin conductance monitoring during waking hours
Number of subjects: 24
Study: 8758159

Group type: EXPERIMENTAL
Intervention: Piroxicam with alfentanil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alfentanil alone
Number of subjects: 0
Study: 1949258

Group type: EXPERIMENTAL
Intervention: LongoVital (LV)
Number of subjects: 31
Study: 6524990

Group type: EXPERIMENTAL
Intervention: Malaria prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: No malaria prophylaxis (Control)
Number of subjects: 0
Study: 31335582

Group type: EXPERIMENTAL
Intervention: Teens with ADHD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Teens with TSF
Number of subjects: 0

Group type: COMPARATOR
Intervention: Typically Developing (TD) teens
Number of subjects: 0
Study: 30109908

Group type: EXPERIMENTAL
Intervention: B-GOS® (2.75 g/d)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 27001136

Group type: EXPERIMENTAL
Intervention: Manual Therapy according to the Utrecht School (MTU)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Physiotherapy (PT)
Number of subjects: 181
Study: 23232844

Group type: EXPERIMENTAL
Intervention: Carvedilol plus NAC
Number of subjects: 311

Group type: COMPARATOR
Intervention: Carvedilol
Number of subjects: 311
Study: 21585221

Group type: EXPERIMENTAL
Intervention: Pharmacotherapeutic follow-up programme (PTP)
Number of subjects: 732
Study: 19384757

Group type: EXPERIMENTAL
Intervention: Fibrin glue (Tissucol Duo, Baxter AG, Vienna, Austria)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Suture (7‐0 silk)
Number of subjects: 17
Study: 17061673

Group type: EXPERIMENTAL
Intervention: Third-group chinolone
Number of subjects: 18

Group type: COMPARATOR
Intervention: Clindamycin/Ceftriaxone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 18
Study: 15503071

Group type: EXPERIMENTAL
Intervention: Perception of resources (cognition, health, social network) in young individuals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perception of resources (cognition, health, social network) in old individuals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resource status in both age groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resource loss in young individuals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resource loss in old individuals
Number of subjects: 0
Study: 10833739

Group type: EXPERIMENTAL
Intervention: Fluoxetine (Prozac) with information about weight loss side effects
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Imipramine (Tofranil) with information about weight gain side effects
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fluoxetine (Prozac) without information about weight-related side effects
Number of subjects: 60

Group type: COMPARATOR
Intervention: Imipramine (Tofranil) without information about weight-related side effects
Number of subjects: 60
Study: 9284876

Group type: EXPERIMENTAL
Intervention: Food-record rating
Number of subjects: 78

Group type: COMPARATOR
Intervention: Fat-gram counting
Number of subjects: 78
Study: 8335047

Group type: EXPERIMENTAL
Intervention: Single 1 gram dose of ceftazidime with the induction of anaesthesia
Number of subjects: 764

Group type: EXPERIMENTAL
Intervention: 1 g daily ceftazidime from induction of anaesthesia until removal of the urethral catheter (but ≤ 5 days)
Number of subjects: 764

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 764

Group type: EXPERIMENTAL
Intervention: Ceftazidime-treated groups (both single-dose and multidose)
Number of subjects: 764
Study: 3567048

Group type: EXPERIMENTAL
Intervention: Adenosine infusion at rates of 6.1 mg min‐1 and above
Number of subjects: 6

Group type: COMPARATOR
Intervention: Inosine infusion at dose rates up to 16.8 mg min‐1
Number of subjects: 6
Study: 29455044

Group type: EXPERIMENTAL
Intervention: 80% perioperative inspiratory oxygen fraction
Number of subjects: 1400

Group type: COMPARATOR
Intervention: 30% perioperative inspiratory oxygen fraction
Number of subjects: 1400
Study: 27746224

Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine
Number of subjects: 1761

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1761
Study: 24516018

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (CRT)
Number of subjects: 291
Study: 21979801

Group type: EXPERIMENTAL
Intervention: Sitaxsentan (100 mg/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 19733875

Group type: EXPERIMENTAL
Intervention: Argemone mexicana decoction (AM)
Number of subjects: 301

Group type: COMPARATOR
Intervention: artesunate-amodiaquine (ACT)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Both AM and ACT
Number of subjects: 301
Study: 18404697

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound (EUS)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Computed tomography (CT)
Number of subjects: 40
Study: 19279966

Group type: EXPERIMENTAL
Intervention: NaF/KNO3 dentifrice (Sensodyne ProNamel)
Number of subjects: 25

Group type: COMPARATOR
Intervention: SnF2/SHMP dentifrice (blend-a-med EXPERT GUMS PROTECTION)
Number of subjects: 25
Study: 15051614

Group type: EXPERIMENTAL
Intervention: DHA (4.9 g/d)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: EPA (4.7 g/d)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 42
Study: 12153647

Group type: EXPERIMENTAL
Intervention: Conventional care plus peer support
Number of subjects: 256

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 256
Study: 9772929

Group type: EXPERIMENTAL
Intervention: Anti Gp IIb‐IIIa (Reopro chimeric antibody, Abciximab®)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hirudin and its derivatives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparins
Number of subjects: 0
Study: 8165068

Group type: EXPERIMENTAL
Intervention: Homeopathic medicine
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 2905500

Group type: EXPERIMENTAL
Intervention: Lormetazepam (0.03 mg/kg IV) + ZK 93 426 (0.04 mg/kg IV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lormetazepam (0.03 mg/kg IV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ZK 93 426 (0.04 mg/kg IV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11551875

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 303

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 303
Study: 30574801

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938
Number of subjects: 56
Study: 30192446

Group type: EXPERIMENTAL
Intervention: Behavioral activation via telehealth
Number of subjects: 241

Group type: COMPARATOR
Intervention: Behavioral activation in-person
Number of subjects: 241
Study: 26372539

Group type: EXPERIMENTAL
Intervention: ICD‐9‐CM code for dermatitis due to drug (693.0)
Number of subjects: 1634

Group type: EXPERIMENTAL
Intervention: ICD‐9‐CM code for adverse reaction to drug (995.2)
Number of subjects: 1634

Group type: EXPERIMENTAL
Intervention: ICD‐9‐CM code for anaphylaxis (995.0)
Number of subjects: 1634

Group type: EXPERIMENTAL
Intervention: ICD‐9‐CM code and E code combination
Number of subjects: 1634

Group type: EXPERIMENTAL
Intervention: Overall allergic drug reactions
Number of subjects: 1634

Group type: EXPERIMENTAL
Intervention: Frequency of allergic drug reactions
Number of subjects: 1634
Study: 24643895

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03%
Number of subjects: 209

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 209
Study: 23283449

Group type: EXPERIMENTAL
Intervention: Uniform multidrug therapy (U‐MDT) for leprosy
Number of subjects: 858

Group type: COMPARATOR
Intervention: Regular treatment regimen for leprosy
Number of subjects: 858
Study: 20819222

Group type: EXPERIMENTAL
Intervention: Innovative implementation strategy including a computerized decision support system (BOS)
Number of subjects: 472

Group type: COMPARATOR
Intervention: Common strategy of professional audit and feedback
Number of subjects: 472
Study: 17668537

Group type: EXPERIMENTAL
Intervention: Oral valacyclovir suppressive therapy (1 g once daily for 6 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral valacyclovir episodic therapy (two 2-g doses separated by 12 hours at first sign of prodrome for 6 months)
Number of subjects: 0
Study: 16265352

Group type: EXPERIMENTAL
Intervention: Immediate treatment with chemotherapy (weekly 5-fluorouracil and leucovorin 500 and 20 mg m(‐2), respectively)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Immediate treatment with chemotherapy (daily x 5 Mayo Clinic schedule 425 and 20 mg m(‐2), respectively)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Immediate treatment with chemotherapy (Mayo schedule)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Delayed treatment (at onset of predefined symptoms)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Immediate treatment with chemotherapy
Number of subjects: 168

Group type: COMPARATOR
Intervention: Delayed treatment
Number of subjects: 168
Study: 12075639

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) ointment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 10426172

Group type: EXPERIMENTAL
Intervention: Breast milk
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Formula
Number of subjects: 137

Group type: COMPARATOR
Intervention: Intervention children (previously formula-fed)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control children (previously formula-fed)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Intervention children (previously breastfed)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control children (previously breastfed)
Number of subjects: 137
Study: 8672820

Group type: EXPERIMENTAL
Intervention: 20% lipid emulsion amphotericin B (1 mg/mL)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional amphotericin B (0.1 mg/mL) in dextrose 5% solution
Number of subjects: 20
Study: 2223742

Group type: EXPERIMENTAL
Intervention: Dietary nitrate intake (0.83 to 5.20 mmol/d)
Number of subjects: 6
Study: 365213

Group type: EXPERIMENTAL
Intervention: Bromhexine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 31833259

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT) without interval debulking surgery
Number of subjects: 224

Group type: COMPARATOR
Intervention: Interval debulking surgery (IDS) after NACT
Number of subjects: 224
Study: 31453631

Group type: EXPERIMENTAL
Intervention: Probiotic mixture
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 28734659

Group type: EXPERIMENTAL
Intervention: Vacuum-assisted closure (VAC)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Traditional wrap and bandages
Number of subjects: 51
Study: 25697236

Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: Guided self‐help
Number of subjects: 536

Group type: COMPARATOR
Intervention: Antidepressants
Number of subjects: 536

Group type: COMPARATOR
Intervention: Bibliotherapy
Number of subjects: 536
Study: 24634631

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 22011907

Group type: EXPERIMENTAL
Intervention: briakinumab (200 mg at weeks 0 and 4 and 100 mg at week 8)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: briakinumab 100 mg every 4 weeks (q4-wk)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: briakinumab 100 mg every 12 weeks (q12-wk)
Number of subjects: 76

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 76
Study: 19576353

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17180286

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography (EUS)
Number of subjects: 100
Study: 15128701

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 0
Study: 15186523

Group type: EXPERIMENTAL
Intervention: Hib conjugate vaccine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Not vaccinated (control group)
Number of subjects: 80
Study: 11210884

Group type: COMPARATOR
Intervention: Parenteral piperacillin/tazobactam (3.375 g every 6 hours for 48 h)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Parenteral piperacillin/tazobactam plus topical piperacillin/tazobactam administered as a mouthwash immediately before surgery and once a day for 2 days postoperatively
Number of subjects: 62
Study: 9467534

Group type: EXPERIMENTAL
Intervention: MK-677 25 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 7948820

Group type: EXPERIMENTAL
Intervention: IFN-alpha-2a therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Liver biopsies from patients with HC/HNANB infection
Number of subjects: 0
Study: 3283625

Group type: EXPERIMENTAL
Intervention: Low-dose IFN alpha-2c (1.2 x 10 IU/m x 28 days s.c. or lower)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Pulsatile IFN on 7 consecutive days within a 28-day period
Number of subjects: 84

Group type: COMPARATOR
Intervention: Daily IFN
Number of subjects: 84
Study: 30188590

Group type: EXPERIMENTAL
Intervention: 0.5 mL sucrose (25% in South Africa, 24% in Norway)
Number of subjects: 53

Group type: COMPARATOR
Intervention: 0.2 mL sucrose (25% in South Africa, 24% in Norway)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 0.5 mL sucrose
Number of subjects: 53

Group type: COMPARATOR
Intervention: 0.2 mL sucrose
Number of subjects: 53
Study: 28142387

Group type: EXPERIMENTAL
Intervention: Supported employment
Number of subjects: 85

Group type: COMPARATOR
Intervention: Traditional vocational program
Number of subjects: 85
Study: 26694748

Group type: EXPERIMENTAL
Intervention: Support by specialized oncology nurses for eight weeks after discharge from hospital by telephone, consisting of symptom monitoring, counselling on self-assessment and self-management, and dealing with individual resources for coping and psychosocial well-being.
Number of subjects: 370

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 370
Study: 23228922

Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy (BB)
Number of subjects: 5628

Group type: COMPARATOR
Intervention: No beta-blocker therapy
Number of subjects: 5628

Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy (BB) in high-risk patients (GRACE risk scores ≥121)
Number of subjects: 5628

Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy (BB) in high-risk patients (administered diuretics)
Number of subjects: 5628

Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy (BB) in lower risk patients
Number of subjects: 5628
Study: 20830695

Group type: EXPERIMENTAL
Intervention: 8 sessions with trauma narrative (TN)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: 8 sessions without TN
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: 16 sessions with TN
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: 16 sessions without TN
Number of subjects: 210
Study: 17761505

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES) with ISA
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES) without ISA
Number of subjects: 325